The partial "hem/hcp/pages/vpodium.html" was not found, as such it will not be rendered.
Proposed Mechanism of Action
CD20 is an important target for NHL and CLL therapy
- CD20 is a cell surface antigen, or protein, that is expressed on the surface of most normal and malignant B cells1
- CD20 is a stable target that is not shed, found freely circulating in plasma, or internalized upon antibody binding2
- Both NHL and CLL cells express surface CD20—NHL does so to a greater degree3
RITUXAN is an anti-CD20 monoclonal antibody
- First FDA-approved monoclonal antibody for the treatment of cancer
- RITUXAN specifically targets and binds tightly to CD201
RITUXAN induces B-cell destruction through 3 proposed mechanisms
- These proposed ways include4
- ADCC: Natural killer cells, T cells, and macrophages are involved in recognizing and killing antibody-labeled target cells, leading to cell lysis
- CDC: Binding of the antibody recruits complement proteins, which punch holes in the cell membrane, flooding the cell and leading to cell lysis
- Apoptosis: Binding of the antibody signals the cell to self-destruct
- All 3 of these proposed mechanisms of action are potentially important contributors to targeted B-cell destruction4
- RITUXAN® (Rituximab) full prescribing information, Genentech, Inc., 2013.
- Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445.
- Yee KWL, O’Brien SM. Chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc. 2006;81:1105-1129.
- Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002;29(suppl 2):2-9.